UNITED STATES NEWS

Novavax: Large study finds COVID-19 shot about 90% effective

Jun 14, 2021, 6:00 PM | Updated: Jun 15, 2021, 8:17 am
FILE - In this Wednesday, Oct. 7, 2020, file photo, a Phase 3 Novavax coronavirus vaccine trial vol...

FILE - In this Wednesday, Oct. 7, 2020, file photo, a Phase 3 Novavax coronavirus vaccine trial volunteer is given an injection at St George's University hospital in London. Novavax says its vaccine appears effective against COVID-19 in a large study, including against variants. Results from the study in the U.S. and Mexico were released on Monday, June 14, 2021. (AP Photo/Alastair Grant, File)

(AP Photo/Alastair Grant, File)

Vaccine maker Novavax said Monday its COVID-19 shot was highly effective against the disease and also protected against variants in a large study in the U.S. and Mexico, potentially offering the world yet another weapon against the virus at a time when developing countries are desperate for doses.

The two-shot vaccine was about 90% effective overall, and preliminary data showed it was safe, the American company said. That would put the vaccine about on par with Pfizer’s and Moderna’s.

While demand for COVID-19 shots in the U.S. has dropped off dramatically and the country has more than enough doses to go around, the need for more vaccines around the world remains critical. The Novavax vaccine, which is easy to store and transport, is expected to play an important role in boosting supplies in poor parts of the world.

That help is still months away, however. The company, which has been plagued by raw-material shortages that have hampered production, said it plans to seek authorization for the shots in the U.S., Europe and elsewhere by the end of September and will be able to produce up to 100 million doses a month by then.

“Many of our first doses will go to … low- and middle-income countries, and that was the goal to begin with,” Novavax CEO Stanley Erck said.

While more than half of the U.S. population has had at least one vaccine dose, less than 1% of people in the developing world have had one shot, according to a data collection effort run in part by the University of Oxford.

The Novavax shot stands to become the fifth Western-developed COVID-19 vaccine to win clearance. The Pfizer, Moderna and Johnson & Johnson vaccines are already authorized for use in the U.S. and Europe. Europe also uses AstraZeneca’s formula.

Novavax’s study involved nearly 30,000 people ages 18 and up. Two-thirds received two doses of the vaccine, three weeks apart, and the rest got dummy shots. Nearly half the volunteers were Black, Hispanic, Asian American or Native American, and 6% of participants were in Mexico. Altogether, 37% had health problems that made them high risk, and 13% were 65 or older.

There were 77 cases of COVID-19 — 14 in the group that got the vaccine, the rest in volunteers who received the dummy shots. None in the vaccine group had moderate or severe disease, compared with 14 in the placebo group. One person in that group died.

The vaccine was similarly effective against several variants, including the one first detected in Britain that is now dominant in the U.S., and in high-risk populations, including the elderly, people with other health problems and front-line workers in hospitals and meatpacking plants.

“These consistent results provide much confidence in the use of this vaccine for the global population,” said Dr. Paul Heath, director of the Vaccine Institute at the University of London and St. George’s Hospital.

Side effects were mostly mild — tenderness and pain at the injection site. There were no reports of unusual blood clots or heart problems, Erck said.

A study underway in Britain is testing which of several vaccines, including Novavax’s, works best as a booster shot for people who received the Pfizer or AstraZeneca formula. Industry analyst Kelechi Chikere said the Novavax shot could become a “universal booster” because of its high effectiveness and mild side effects.

Novavax reported the results in a news release and plans to publish them in a medical journal, where they will be vetted by independent experts. The Gaithersburg, Maryland-based company previously released findings from smaller studies in Britain and South Africa.

COVID-19 vaccines train the body to recognize the coronavirus, especially the spike protein that coats it, and get ready to fight the virus off. The Novavax vaccine is made with lab-grown copies of that protein. That’s different from some of the other vaccines now widely used, which include genetic instructions for the body to make its own spike protein.

The Novavax vaccine can be stored in standard refrigerators, making it easier to distribute.

As for the shortages that delayed manufacturing, Erck said those were due to restrictions on shipments from other countries.

“That’s opening up,” he said, adding that Novavax now has weeks’ worth of needed materials in its factories, up from just one week.

The company has committed to supplying 110 million doses to the U.S. over the next year and a total of 1.1 billion doses to developing countries.

In May, vaccines alliance Gavi, a leader of the U.N.-backed COVAX project to supply shots to poorer countries, announced it signed an agreement to buy 350 million doses of Novavax’s formula. COVAX is facing a critical shortage of vaccines after its biggest supplier in India suspended exports until the end of the year.

Novavax has been working on developing vaccines for more than three decades but hasn’t brought one to market. Its coronavirus vaccine work is partly funded by the U.S. government.

Dr. Peter English, a vaccine expert previously with the British Medical Association, called the Novavax results “excellent news.” English said that because vaccine production is complicated, it’s crucial to have as many shots as possible.

“Any minor imperfection in the production plant can shut down the production for days or weeks,” he said in a statement. “The more different manufacturers we have producing vaccine, the more likely it is we will have availability of vaccines.”

He said it was also encouraging news that Novavax would be able to adapt its vaccine to any potentially worrying variants in the future if necessary.

___

Follow Linda A. Johnson on Twitter: LindaJ_onPharma

___

AP Medical Writer Maria Cheng contributed to this report.

___

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.

Copyright © The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Lifetime Windows & Doors

              FILE - In this Wednesday, Oct. 7, 2020, file photo, a Phase 3 Novavax coronavirus vaccine trial volunteer is given an injection at St George's University hospital in London. Novavax says its vaccine appears effective against COVID-19 in a large study, including against variants. Results from the study in the U.S. and Mexico were released on Monday, June 14, 2021. (AP Photo/Alastair Grant, File)
            
              FILE - In this Wednesday, Oct. 7, 2020, file photo, a vial of the Phase 3 Novavax coronavirus vaccine is seen ready for use in the trial at St. George's University hospital in London. Novavax says its vaccine appears effective against COVID-19 in a large study, including against variants. Results from the study in the U.S. and Mexico were released on Monday, June 14, 2021. (AP Photo/Alastair Grant, File)
            
              FILE - In this Wednesday, Oct. 7, 2020, file photo, a vial of the Phase 3 Novavax coronavirus vaccine is seen ready for use in the trial at St. George's University hospital in London. Novavax says its vaccine appears effective against COVID-19 in a large study, including against variants. Results from the study in the U.S. and Mexico were released on Monday, June 14, 2021. (AP Photo/Alastair Grant, File)
            
              FILE - In this Wednesday, Oct. 7, 2020, file photo, a Phase 3 Novavax coronavirus vaccine trial volunteer is given an injection at St George's University hospital in London. Novavax says its vaccine appears effective against COVID-19 in a large study, including against variants. Results from the study in the U.S. and Mexico were released on Monday, June 14, 2021. (AP Photo/Alastair Grant, File)
            
              FILE - In this Wednesday, Oct. 7, 2020, file photo, a Phase 3 Novavax coronavirus vaccine trial volunteer is given an injection at St George's University hospital in London. Novavax says its vaccine appears effective against COVID-19 in a large study, including against variants. Results from the study in the U.S. and Mexico were released on Monday, June 14, 2021. (AP Photo/Alastair Grant, File)
            
              FILE - In this Wednesday, Oct. 7, 2020, file photo, a vial of the Phase 3 Novavax coronavirus vaccine is seen ready for use in the trial at St. George's University hospital in London. Novavax says its vaccine appears effective against COVID-19 in a large study, including against variants. Results from the study in the U.S. and Mexico were released on Monday, June 14, 2021. (AP Photo/Alastair Grant, File)
            
              FILE - In this Wednesday, Oct. 7, 2020, file photo, a Phase 3 Novavax coronavirus vaccine trial volunteer is given an injection at St George's University hospital in London. Novavax says its vaccine appears effective against COVID-19 in a large study, including against variants. Results from the study in the U.S. and Mexico were released on Monday, June 14, 2021. (AP Photo/Alastair Grant, File)
            
              FILE - In this Wednesday, Oct. 7, 2020, file photo, a vial of the Phase 3 Novavax coronavirus vaccine is seen ready for use in the trial at St. George's University hospital in London. Novavax says its vaccine appears effective against COVID-19 in a large study, including against variants. Results from the study in the U.S. and Mexico were released on Monday, June 14, 2021. (AP Photo/Alastair Grant, File)
            
              FILE - In this Wednesday, Oct. 7, 2020, file photo, a Phase 3 Novavax coronavirus vaccine trial volunteer is given an injection at St George's University hospital in London. Novavax says its vaccine appears effective against COVID-19 in a large study, including against variants. Results from the study in the U.S. and Mexico were released on Monday, June 14, 2021. (AP Photo/Alastair Grant, File)
            
              FILE - In this Wednesday, Oct. 7, 2020, file photo, a vial of the Phase 3 Novavax coronavirus vaccine is seen ready for use in the trial at St. George's University hospital in London. Novavax says its vaccine appears effective against COVID-19 in a large study, including against variants. Results from the study in the U.S. and Mexico were released on Monday, June 14, 2021. (AP Photo/Alastair Grant, File)
            
              FILE - In this Wednesday, Oct. 7, 2020, file photo, a Phase 3 Novavax coronavirus vaccine trial volunteer is given an injection at St George's University hospital in London. Novavax says its vaccine appears effective against COVID-19 in a large study, including against variants. Results from the study in the U.S. and Mexico were released on Monday, June 14, 2021. (AP Photo/Alastair Grant, File)
            
              FILE - In this Wednesday, Oct. 7, 2020, file photo, a vial of the Phase 3 Novavax coronavirus vaccine is seen ready for use in the trial at St. George's University hospital in London. Novavax says its vaccine appears effective against COVID-19 in a large study, including against variants. Results from the study in the U.S. and Mexico were released on Monday, June 14, 2021. (AP Photo/Alastair Grant, File)
            
              FILE - In this Wednesday, Oct. 7, 2020, file photo, a Phase 3 Novavax coronavirus vaccine trial volunteer is given an injection at St George's University hospital in London. Novavax says its vaccine appears effective against COVID-19 in a large study, including against variants. Results from the study in the U.S. and Mexico were released on Monday, June 14, 2021. (AP Photo/Alastair Grant, File)
            
              FILE - In this Wednesday, Oct. 7, 2020, file photo, a vial of the Phase 3 Novavax coronavirus vaccine is seen ready for use in the trial at St. George's University hospital in London. Novavax says its vaccine appears effective against COVID-19 in a large study, including against variants. Results from the study in the U.S. and Mexico were released on Monday, June 14, 2021. (AP Photo/Alastair Grant, File)
            
              FILE - In this Wednesday, Oct. 7, 2020, file photo, a Phase 3 Novavax coronavirus vaccine trial volunteer is given an injection at St George's University hospital in London. Novavax says its vaccine appears effective against COVID-19 in a large study, including against variants. Results from the study in the U.S. and Mexico were released on Monday, June 14, 2021. (AP Photo/Alastair Grant, File)
            
              FILE - In this Wednesday, Oct. 7, 2020, file photo, a vial of the Phase 3 Novavax coronavirus vaccine is seen ready for use in the trial at St. George's University hospital in London. Novavax says its vaccine appears effective against COVID-19 in a large study, including against variants. Results from the study in the U.S. and Mexico were released on Monday, June 14, 2021. (AP Photo/Alastair Grant, File)
            
              FILE - In this Wednesday, Oct. 7, 2020, file photo, a Phase 3 Novavax coronavirus vaccine trial volunteer is given an injection at St George's University hospital in London. Novavax says its vaccine appears effective against COVID-19 in a large study, including against variants. Results from the study in the U.S. and Mexico were released on Monday, June 14, 2021. (AP Photo/Alastair Grant, File)
            
              FILE - In this Wednesday, Oct. 7, 2020, file photo, a vial of the Phase 3 Novavax coronavirus vaccine is seen ready for use in the trial at St. George's University hospital in London. Novavax says its vaccine appears effective against COVID-19 in a large study, including against variants. Results from the study in the U.S. and Mexico were released on Monday, June 14, 2021. (AP Photo/Alastair Grant, File)
            
              FILE - In this Wednesday, Oct. 7, 2020, file photo, a Phase 3 Novavax coronavirus vaccine trial volunteer is given an injection at St George's University hospital in London. Novavax says its vaccine appears effective against COVID-19 in a large study, including against variants. Results from the study in the U.S. and Mexico were released on Monday, June 14, 2021. (AP Photo/Alastair Grant, File)
            
              FILE - In this Wednesday, Oct. 7, 2020, file photo, a vial of the Phase 3 Novavax coronavirus vaccine is seen ready for use in the trial at St. George's University hospital in London. Novavax says its vaccine appears effective against COVID-19 in a large study, including against variants. Results from the study in the U.S. and Mexico were released on Monday, June 14, 2021. (AP Photo/Alastair Grant, File)
            
              FILE - In this Wednesday, Oct. 7, 2020, file photo, a Phase 3 Novavax coronavirus vaccine trial volunteer is given an injection at St George's University hospital in London. Novavax says its vaccine appears effective against COVID-19 in a large study, including against variants. Results from the study in the U.S. and Mexico were released on Monday, June 14, 2021. (AP Photo/Alastair Grant, File)
            
              FILE - In this Wednesday, Oct. 7, 2020, file photo, a vial of the Phase 3 Novavax coronavirus vaccine is seen ready for use in the trial at St. George's University hospital in London. Novavax says its vaccine appears effective against COVID-19 in a large study, including against variants. Results from the study in the U.S. and Mexico were released on Monday, June 14, 2021. (AP Photo/Alastair Grant, File)
            
              FILE - In this Wednesday, Oct. 7, 2020, file photo, a Phase 3 Novavax coronavirus vaccine trial volunteer is given an injection at St George's University hospital in London. Novavax says its vaccine appears effective against COVID-19 in a large study, including against variants. Results from the study in the U.S. and Mexico were released on Monday, June 14, 2021. (AP Photo/Alastair Grant, File)
            
              FILE - In this Wednesday, Oct. 7, 2020, file photo, a vial of the Phase 3 Novavax coronavirus vaccine is seen ready for use in the trial at St. George's University hospital in London. Novavax says its vaccine appears effective against COVID-19 in a large study, including against variants. Results from the study in the U.S. and Mexico were released on Monday, June 14, 2021. (AP Photo/Alastair Grant, File)
            
              FILE - In this Wednesday, Oct. 7, 2020, file photo, a Phase 3 Novavax coronavirus vaccine trial volunteer is given an injection at St George's University hospital in London. Novavax says its vaccine appears effective against COVID-19 in a large study, including against variants. Results from the study in the U.S. and Mexico were released on Monday, June 14, 2021. (AP Photo/Alastair Grant, File)
            
              FILE - In this Wednesday, Oct. 7, 2020, file photo, a vial of the Phase 3 Novavax coronavirus vaccine is seen ready for use in the trial at St. George's University hospital in London. Novavax says its vaccine appears effective against COVID-19 in a large study, including against variants. Results from the study in the U.S. and Mexico were released on Monday, June 14, 2021. (AP Photo/Alastair Grant, File)

United States News

President Joe Biden and first lady Jill Biden walk on the South Lawn of the White House in Washingt...
Associated Press

White House invites in state lawmakers before 2023 sessions

WASHINGTON (AP) — The White House is playing host to roughly 50 Democratic state lawmakers from 31 states this week as legislatures prepare for their upcoming sessions, aiming to talk over strategy on top issues like climate change, gun violence, abortion rights and voting rights. Those expected to attend the meetings on Tuesday and Wednesday […]
4 hours ago
FILE - Virginia Gov. Glenn Youngkin speaks to supporters as he attends a campaign rally on Monday, ...
Associated Press

Youngkin’s early shine faces test as he eyes White House bid

RICHMOND, Va. (AP) — Glenn Youngkin swept into office as a Republican sensation with a fresh formula for victory as the GOP contemplated its future beyond Donald Trump. But one year after Youngkin became the first Republican in more than a decade to win the Virginia governorship, some in his party believe the shine of […]
4 hours ago
FILE - President Joe Biden speaks about manufacturing jobs and the economy at SK Siltron CSS, a com...
Associated Press

Biden to visit Arizona computer chip site, highlight jobs

President Joe Biden on Tuesday plans to visit the building site for a new computer chip plant in Arizona, using it as a chance to emphasize how his policies are fostering job growth in what could be a challenge to the incoming Republican House majority. Biden has staked his legacy in large part on major […]
4 hours ago
Visitors tour past military vehicles carrying the Dong Feng 41 and DF-17 ballistic missiles at an e...
Associated Press

China blasts US report, reiterates ‘no 1st use’ nuke policy

BEIJING (AP) — China strictly adheres to its policy of no first use of nuclear weapons “at any time and under any circumstances,” its Defense Ministry said Tuesday in a scathing response to a U.S. report alleging a major buildup in Beijing’s nuclear capabilities. The Pentagon last week released an annual China security report that […]
4 hours ago
FILE - EPA Administrator Michael Regan stands near the Marathon Petroleum Refinery as he conducts a...
Associated Press

EPA head visits WVa city that had 10-year water advisory

The head of the federal Environmental Protection Agency is scheduled Tuesday to visit a West Virginia county where some residents recently got access to clean water after years of having to boil it before drinking because of persistent infrastructure issues. EPA Administrator Michael Regan will speak with community members in McDowell County about drinking water […]
4 hours ago
A currency trader passes by screens showing the Korea Composite Stock Price Index (KOSPI), left, an...
Associated Press

Asian shares lower as strong data hit hopes for dovish Fed

BANGKOK (AP) — Stocks were mostly lower in Asia on Tuesday after Wall Street pulled back as surprisingly strong economic reports highlighted the difficulty of the Federal Reserve’s fight against inflation. Tokyo rose, Shanghai was flat and other regional markets declined. U.S. futures gained and oil prices also advanced. Adding to worries over the potential […]
4 hours ago

Sponsored Articles

...
Day & Night Air Conditioning, Heating and Plumbing

Prep the plumbing in your home just in time for the holidays

With the holidays approaching, it's important to know when your home is in need of heating and plumbing updates before more guests start to come around.
(Desert Institute for Spine Care photo)...
DESERT INSTITUTE FOR SPINE CARE

Why DISC is world renowned for back and neck pain treatments

Fifty percent of Americans and 90% of people at least 50 years old have some level of degenerative disc disease.
...
Quantum Fiber

Stream 4K and more with powerful, high-speed fiber internet

Picking which streaming services to subscribe to are difficult choices, and there is no room for internet that cannot handle increased demands.
Novavax: Large study finds COVID-19 shot about 90% effective